Wegovy

News

Novo Nordisk's site in Clayton, North Carolina

Novo Nordisk pledges $4.1bn for US injectables plant

Novo Nordisk has gone up another gear in its drive to boost manufacturing capacity for its fast-growing GLP-1 agonist drugs, announcing plans to build a $4.1 billion fill-and-finish facilit

News

Novo Nordisk’s chief executive Lars Fruergaard Jørgensen

Novo Nordisk CEO agrees to testify on semaglutide pricing

Novo Nordisk’ chief executive Lars Fruergaard Jørgensen has agreed to appear at a Senate hearing later this year to defend the pricing of the group’s semaglutide-based therapies for diabete

News

Scotland first UK nation to clear Mounjaro use for obesity

Scotland has become the first country in the UK to back NHS use of Eli Lilly’s obesity therapy Mounjaro, clearing it to assist weight management in eligible patients.

News

Obesity drugs could bankrupt US healthcare, says Sanders

A report issued by the office of US Senator Bernie Sanders has claimed that the high prices being charged for new GLP-1 agonist-based obesity therapies like Novo Nordisk’s

News

Semaglutide heart benefits may go beyond weight loss

New data suggests that the benefits of Novo Nordisk’s GLP-1 agonist semaglutide in preventing cardiovascular diseases may not simply be a result of weight loss.

News

Wegovy sales double, as starting restrictions start to lift

Novo Nordisk’s breakneck sales growth has continued in the first quarter of this year with a 24% increase that was helped by a doubling in turnover of obesity blockbuster Wegovy

Novo Nordisk pledges $4.1bn for US injectables plant

Novo Nordisk CEO agrees to testify on semaglutide pricing

Scotland first UK nation to clear Mounjaro use for obesity

Obesity drugs could bankrupt US healthcare, says Sanders

Semaglutide heart benefits may go beyond weight loss

Wegovy sales double, as starting restrictions start to lift

OpenBind unveils its first AI model for drug discovery

Discover a new era of healthcare panel engagement: Grounded ...

Wegovy

Editor's Picks